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Abstract
Background: Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells, and its expression has been
correlated with increased tumour angiogenesis. Although numerous publications dealing with the measurement of circulating
VEGF for diagnostic and therapeutic monitoring have been published, the relationship between the production of tissue VEGF
and its concentration in blood is still unclear. The aims of this study were to determine: 1) The expression pattern of VEGF
isoforms at the protein level in colorectal and lung adenocarcinoma in comparison to the pattern in corresponding adjacent
normal tissues 2) The relationship between the expression pattern of VEGF and total level of circulating VEGF in the blood to
clarify whether the results of measuring circulating VEGF can be used to predict VEGF expression in tumour tissues.
Methods: Ninety-four tissue samples were obtained from patients, 76 colorectal tumour tissues and 18 lung tumour tissues.
VEGF protein expression pattern and total circulating VEGF were examined using western blot and capture ELISA, respectively.
Results: Three major protein bands were predominately detected in tumour samples with an apparent molecular mass under
reducing conditions of 18, 23 and 26 kDa. The 18 kDa VEGF protein was expressed equally in both normal and colorectal
tumour tissues and predominately expressed in normal tissues of lung, whereas the 23 and 26 kDa protein was only detected
at higher levels in tumour tissues. The 18, 23 and 26 kDa proteins are believed to represent the VEGF121, the VEGF165 and the
VEGF189, respectively. There was a significant correlation of the expression of VEGF165 with a smaller tumour size maximum
diameter <5 cm (p < 0.05), and there was a significant correlation of VEGF189 with advanced clinical stage of colorectal tumours.
The measurement of total circulating VEGF in serum revealed that cancer patients significantly (p < 0.001) possessed a higher
level of circulating VEGF (1081 ± 652 pg/ml in colorectal and 1,251 ± 568 pg/ml in lung) than a healthy volunteer group (543 ±
344 pg/ml). No correlation between the level of circulating VEGF and the pathologic features of tumours was observed.
Conclusion: Our findings indicate that the expression patterns of VEGF isoforms are altered during tumourigenesis as certain
isoform overexpression in tumour tissues correlated with tumour progression indicating their important role in tumour
development. However, measurement of VEGF in the circulation as a prognostic marker needs to be carefully evaluated as the
cell-associated isoform (VEGF189), but not the soluble isoform (VEGF121 and VEGF165) appears to play important role in tumour
progression.
Published: 04 October 2005
BMC Cancer 2005, 5:128 doi:10.1186/1471-2407-5-128
Received: 20 June 2005
Accepted: 04 October 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/128
© 2005 Cressey et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:128 http://www.biomedcentral.com/1471-2407/5/128
Page 2 of 8
(page number not for citation purposes)
Background
VEGF plays a crucial role in tumour expansion by initiat-
ing permeabilization of blood vessels, by extravasation of
plasma proteins, by invasion of stromal cells, and by caus-
ing the sprouting of new blood vessels that supply the
tumour with oxygen and nutrients [1]. As a result of alter-
native splicing, 6 VEGF isoforms of 121, 145, 165, 183,
189 and 206 amino acids are produced from a single gene
[2]. Due to differential incorporation of basic residues
encoded by exon 6 and 7, VEGF isoforms differ in their
heparin-binding properties, membrane association, and
secretion [3]. VEGF121, which lacks the basic residues of
both exons, does not bind heparin-containing cell surface
proteoglycan [4], and is freely soluble. VEGF165 is also
secreted. However, cationic residues in exon 7 enable
VEGF165 to bind heparin, thus, some remains bound to
the cell surface or to extracellular matrix. VEGF189 which
retain both exons, has the highest affinity for heparin and
therefore, remains tightly cell associated.
Detection of circulating VEGF has been investigated as a
potential serum diagnostic marker for malignant disease
and for inflammation [5]. Increased serum concentrations
of free VEGF have been measured in various types of can-
cer, including brain, lung, gastrointestinal, hepatobiliary,
renal, and ovarian cancers [6]. However, the relationship
between the pattern of the production of VEGF protein
isoforms in tumour tissues and their concentration in the
circulation is still unclear.
A number of studies have shown that expression of certain
VEGF transcripts are correlated with tumour progression.
Increased mRNA expression of VEGF189 is correlated with
poor prognosis in osteosarcoma [7] and non-small cell
lung cancer [8,9], whereas expression of VEGF121 was cor-
related with lymph node metastasis in primary lung
tumours [10]. Although increases of certain VEGF tran-
scripts have been demonstrated to correlate with the pro-
gression of various tumours, the actual protein levels of
the different VEGF isoforms and their significance during
cellular transformation are unknown. Moreover, it has
been suggested that elevated protein expression in tumour
tissues was mediated by both enhanced transcription [11]
and translation [12]. Thus, in order to understand the role
of VEGF in tumour progression, it is important to investi-
gate expression of different VEGF isoforms at the protein
level during tumourigenesis. To our knowledge, no stud-
ies focusing on the VEGF isoform pattern at the protein
level and their relationship with respect to total VEGF in
the circulation have been reported.
Therefore, the aims of this study were to determine: 1) The
protein expression pattern of VEGF isoforms in colorectal
and lung tumours in comparison to the corresponding
adjacent normal tissues in order to understand whether
specific VEGF protein isoforms play an important role
during tumourigenesis. 2) The relationship between the
expression pattern of VEGF and the level of total circulat-
ing VEGF in the blood.
Methods
Selection of patients and sample
Between April 2002 and June 2004, samples were col-
lected from cancer patients at Maharaj Nakorn Chiang
Mai Hospital, which comprised 76 colorectal tumours
(averaged age was 59 ± 15.2 (mean ± SD), 46 females and
30 males) and 18 non-small cell lung tumours (averaged
age was 55 ± 14.6, 10 females and 8 males, 9 adenocarci-
nomas and 9 squamous cell carcinomas). In each case,
adjacent normal tissue was collected. These specimens
were immediately placed in vials, frozen in embedded
medium for the preservation of cell integrity, and stored
at -80°C until analyzed. Samples were graded by a pathol-
ogist according to the pathological features of the
tumours, which included tumour size in maximal diame-
ter, histological grading, lymph node metastasis, distant
metastasis, and tumour staging (the AJCC TNM
classification).
To avoid pre-analytical sample-to-sample variation due to
blood collecting procedures, each blood sample was
allowed to clot for at least 4 hrs before collecting serum as
it has been reported that the release of VEGF during clot-
ting period would have reached a plateau by this time
[13]. Of 94 patients recruited in this study, serums were
obtained from 56 cancer patients prior to the operation
(38 from colorectal cancer patients, 18 from lung cancer
patients). The age range of cancer patients was 58 ± 12.5
years and composed of 32 females and 24 males.
Serums were also collected from 47 healthy volunteers
with no history of rheumatoid arthritis or recent preg-
nancy, trauma, surgery (within 1 month) or menstruation
(within 1 week) using the same procedure as for the can-
cer patients so that a comparison could be made. The age
range of healthy volunteers was 51 ± 10.9 (mean ± SD)
years, composed of 20 female and 27 males. All serums
were stored at -70°C until analyzed. The study was
approved by the ethical committee of the Faculty of Med-
icine, Chiang Mai University (document number 56/
2545).
Western blotting
Western blotting was performed to evaluate the expres-
sion of VEGF in each tissue. Frozen tissues were thawed,
cut into small pieces and homogenized in SDS lysis buffer
(0.5 M Tris-HCl pH 6.8, 2% SDS (w/v) and 10% glycerol
(v/v)) containing a protease inhibitors cocktail (104 mM
AEBSF, 0.08 mM aprotinin, 2.2 mM leupeptin, 3.6 mM
bestatin, 1.5 mM pepstatin A, 1.4 mM E-64; Sigma,BMC Cancer 2005, 5:128 http://www.biomedcentral.com/1471-2407/5/128
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U.S.A). The tissue homogenate was then centrifuged at
10,000 g for 15 minutes at 4°C, after which the superna-
tant was removed and the protein concentration of the
supernatant was estimated using the BCA protein assay kit
(PIERCE, U.S.A). Twenty-five micrograms of protein from
the tumour tissue and normal tissue from each patient
was resolved on a 10% SDS polyacrylamide gel under
reducing conditions and electrotransferred onto a nitro-
cellulose membrane (Biorad, U.S.A). After blocking with
5% non-fat milk in TBS containing 0.05% Tween-20 (TBS-
Tween) for 1 hour, the membrane was incubated with
anti-VEGF antibodies (Santa Cruz Biotechnology, Inc.,
USA, Cat. no. SC-152, dilution 1:1000) for 1 hour. After
washing with TBS-Tween, the membrane was incubated
for 1 hour at RT with horseradish peroxidase-conjugated
goat anti-mouse IgG (Dako, U.S.A). After washing with
TBS-Tween, immunoreactive protein was visualized with
a chemiluminescence-based procedure using the ECL Plus
detection kit according to the manufacturer's protocol
(Amersham, U.S.A). In order to examine the equality of
protein loaded, the amount of total protein loaded into
each lane was examined by staining with coomassie blue.
Measurement of total VEGF in serum
For the detection of circulating VEGF in serum, enzyme-
linked immunosorbent assay (ELISA) was performed
using two different anti-VEGF antibodies purchased from
R&D system, USA. Briefly, capture antibodies specific for
VEGF (R&D System, cat no. AF293 at concentration 200
ng/ml) was immobilized onto-96-well microtiter plates.
Unbound antibody was removed by washing the plate
and a blocking reagent was added. Following a wash,
recombinant VEGF protein standard (VEGF165) diluted in
PBS containing 5% BSA to various concentrations (75–
2,500 pg/ml), unknown serum and control serum were
then incubated with the solid phase antibodies, which
capture VEGF. After washing away unbound molecules, a
detection antibody specific for VEGF (R&D System, cat no.
MAB293 at concentration 500 ng/ml) was added. After
incubation and washing, HRP-conjugated anti-mouse
immunoglobulin was added. The plate was washed and a
TMB substrate solution (Zymed, USA) was added. After 20
minutes, the color development was stopped and the
intensity of color was measured using a microtiter plate
reader (450 nm). The color developed in proportion to
the amount of bound VEGF. When we measured 20 serum
samples twice in two separated assays, the inter-assay
Representative Western blots showing protein expression pattern of VEGF isoform in (a) colorectal and (b) non-small cell lung  tumour tissues and their corresponding adjacent normal tissues (T, tumor tissues; N, normal tissues) Figure 1
Representative Western blots showing protein expression pattern of VEGF isoform in (a) colorectal and (b) non-small cell lung 
tumour tissues and their corresponding adjacent normal tissues (T, tumor tissues; N, normal tissues).
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variation ranged between 5–10% within the same concen-
tration range. The average recovery of the added recom-
binant VEGF165 ranged between 85–115%, indicating an
acceptable level of specificity of the assay.
Statistical analysis
Total VEGF levels are expressed as mean ± standard devia-
tion. Differences in the circulating VEGF level of two inde-
pendent groups were evaluated using the Mann-Whitney
test. Correlation between VEGF isoform expression and
the pathological features were evaluated using chi-square
test. All the statistical evaluations were performed by
using the SPSS for Window version 10.0 (SPSS, Inc., Chi-
cago, IL, USA).
Results
Pattern of VEGF protein expression in normal and tumour 
tissues of colon and lung
The expression pattern of VEGF isoforms in tumour tis-
sues in comparison to normal tissues determined by west-
ern blot analysis are shown in Figure 1. Three major
protein bands were predominately detected in colorectal
and lung tumour samples with an apparent molecular
mass under reducing conditions of 18 kDa, 23 kDa, and
26 kDa. The 18 kDa VEGF was equally expressed in both
Table 1: Summary of relationship between VEGF isoform expression and pathologic features in colorectal and non-small cell lung 
cancers (p < 0.05 was considered significant)
Pathologic features VEGF isoform (kDa)
VEGF 23 kDa p valuea VEGF 26 kDa p valuea
Colorectal cancer (total 76 cases) 42 (55.3%) 53 (69.7%)
Gender
Female (46 cases) 28 (60.8%) 0.224 32 (69.5%) 0.968
Male (30 cases) 14 (46.7%) 21 (70.0%)
Tumour size
≤ 5 cm (45 cases) 30 (66.7%)b < 0.05 30 (66.7%) 0.483
> 5 cm (31 cases) 12 (38.7%) 23 (74.1%)
Histological differentiation
Well (42 cases) 22 (52.4%) 0.574 28 (66.7%) 0.517
Moderate or Poor (34 cases) 20 (58.8%) 25 (73.5%)
Tumour stage grouping
Early stage (I or II) (34 cases) 23 (67.6%) 0.09 19 (55.9%) < 0.01
Late stage (III or IV) (42 cases) 19 (45.2%) 34 (80.9%)
Metastasis
No (49 cases) 31 (63.3%) 0.059 29 (59.2%) < 0.01
Yes (27 cases) 11 (40.7%) 24 (88.9%)
Lung cancer (total 18 cases) 16 (88.9%) 16 (88.9%)
Gender
Female (10 cases) 8 (80.0%) 0.477 8 (80.0%) 0.477
Male (8 cases) 8 (100.0%) 8(100%)
Tumour size
≤ 5 cm (7 cases) 7 (100.0%) 0.231 7 (100.0%) 0.231
> 5 cm (11 cases) 9 (81.8%) 9 (81.8%)
Histological differentiation
Well (5 cases) 4 (80.0%) 0.490 4 (80.0%) 0.490
Moderate or Poor (13 cases) 12 (92.3%) 12 (93.3%)
Tumour stage grouping
Early stage (I or II) (2 cases) 1 (50.0%) 0.210 0 (0.0%) < 0.01
Late stage (III or IV) (16 cases) 15 (93.8%) 16 (100%)
Metastasis
No (7 cases) 6 (85.7%) 1.00 5 (71.4%) 0.137
Yes (11 cases) 10 (90.9%) 11 (100.9%)
a chi-square test, b percentage in relation to total number of cases in each pathological featuresBMC Cancer 2005, 5:128 http://www.biomedcentral.com/1471-2407/5/128
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normal and tumour tissues of colorectal and predomi-
nately expressed in normal tissue of lung, whereas the 23
and 26 kDa were only detected at higher levels in tumour
tissues of both organs. Expression of the 23 kDa VEGF iso-
form was observed in 55.3% (42 of 76 patients) of color-
ectal tumours and 88.9% (16 of 18 patients) of lung
tumour tissues. Whereas, expression of 26 kDa VEGF iso-
form was detected in 69.7% (53 of 76 patients) and
88.9% (16 of 18 patients) of colorectal and lung tumour
tissues, respectively.
Protein expression patterns of VEGF isoforms in tumour 
tissues of colon and lung in relation to pathological 
features
The two types of cancer were classified according to the
pathologic features, which included tumour sizes in max-
imum diameter, depth of invasion, lymph node metasta-
sis, distant metastasis and histological differentiation.
Expression of the VEGF isoforms in relation to the patho-
logical features of colorectal tumours and lung tumours
are summarized in Table 1.
No significant difference between gender of the VEGF
expression pattern was observed in both types of cancer.
In colorectal cancer, it was found that expression of VEGF
isoform with molecular weight 23 kDa was significantly
correlated with a smaller tumour size (maximum diame-
ter < 5 cm, p < 0.05), whereas the 26 kDa VEGF isoform
was significantly correlated with advanced clinical stage
and metastasis of the tumour (p < 0.01). Expression of the
26 kDa VEGF isoform was also significantly correlated
with advanced clinical stage of non-small cell lung cancer
(p < 0.001). Sixteen (out of 18) lung tumour tissues which
overexpressed 26 kDa VEGF were late stage tumours
(Table 1). No significant difference of the expression pat-
tern of VEGF between different histology type (adenocar-
cinoma and squamous cell carcinoma) was observed
(data not shown).
Levels of circulating VEGF in cancer patients compared to 
healthy volunteers and their relationship to pathological 
features
Preoperative serum was collected from 56 cancer patients;
these included 38 patients with colorectal cancer and 18
with lung cancer. Serum from 47 healthy volunteers was
also collected for comparison. The result showed that can-
cer patients possessed significantly higher level of circulat-
ing VEGF than those in healthy volunteers (Figure 2).
While level of total circulating VEGF in healthy volunteer
was only 543 ± 344 pg/ml, it was 1081 ± 652 pg/ml and
1,251 ± 568 pg/ml in patients with colorectal and lung
cancer, respectively (Table 2). No significant relationship
between the level of circulating VEGF and the pathologi-
cal features was observed (Table 3). Gender also did not
show any impact on circulating level of VEGF (Table 3). In
addition, none of the VEGF isoforms showed a significant
relationship with the serum level of VEGF. Although
colorectal cancer patients with overexpression of VEGF 23
kDa, which is believed to be VEGF165 (one of a secretable
form of VEGF) in tumour tissues, possessed higher levels
of circulating VEGF in serum (1190 ± 752 pg/ml) than
those possessing undetectable level of VEGF165 (875 ± 330
pg/ml), it was not statistically significant (p = 0.207,
Mann-Whitney test).
Discussion
It has become clear that the growth of solid tumours is
dependent on the process of angiogenesis and that VEGF
is a central positive regulator of this process. Most VEGF-
producing cells appear preferentially to express VEGF121,
VEGF165 and VEGF189. In this study, we investigated the
expression pattern of the VEGF protein isoform in color-
ectal tumour tissues and in lung tumour tissues and com-
pared them with the expression pattern of normal tissues
from each organ, respectively. Three major protein bands
with molecular weight 18, 23 and 26 kDa were predomi-
nately detected. The 23-kDa protein band is believed to be
the VEGF165 as this band was at the same position as the
human recombinant VEGF165 protein standard (R&D Sys-
tem, USA) used in this study. Expression of VEGF145 and
VEGF206 is comparatively rare seemingly restricted to cells
of placental origin [14,15]. Therefore, protein bands with
molecular weight of 18 and 26 kDa are assumed to be
VEGF121 [16,17] and VEGF189, respectively.
In colorectal tumours, it was found that VEGF121 was
expressed equally in both tumour and normal tissues,
Serum level of circulating VEGF of colorectal and non-small  cell lung cancer patients in comparison to healthy volunteers Figure 2
Serum level of circulating VEGF of colorectal and non-small 
cell lung cancer patients in comparison to healthy volunteers.
healthy colorectal cancer  lung cancer
0
1000
2000
3000
4000
V
E
G
F
 
c
i
r
c
u
l
a
t
i
n
g
 
l
e
v
e
l
 
(
p
g
/
m
l
)BMC Cancer 2005, 5:128 http://www.biomedcentral.com/1471-2407/5/128
Page 6 of 8
(page number not for citation purposes)
whereas the VEGF165 and VEGF189 were only detected at
higher level in tumour tissues. However in lung tumour,
VEGF121  appeared to be predominately expressed in
normal tissues, whereas VEGF165 and VEGF189 were pre-
dominately expressed in tumours tissues. Protein expres-
sion of VEGF165 correlated significantly with a smaller
tumour size, whereas VEGF189  correlated significantly
with advanced clinical stage and metastasis of the
tumours. Although only 18 lung tumours were investi-
gated in this study, the 26-kDa VEGF isoform was also
overexpressed significantly in advanced stage of the
tumour (Table 1).
Although the regulation of VEGF expression is becoming
well understood, its mode of action, particularly the regu-
lation of expression and distribution of the three primary
isoform (VEGF121, VEGF165  and VEGF189), remains
unclear. It has been demonstrated that overexpression of
smaller isoforms resulted in hemorrhagic events, but the
expression of VEGF189 resulted in increased vessel density
[18]. In this study we found that overexpression of
VEGF189 protein isoform, but not VEGF121 or VEGF165, was
associated with advanced tumour stage. Our data is
consistent with the previous reports where expression of
VEGF189 transcripts was correlated with poor prognosis in
non-small cell lung, osteosarcoma, renal, colorectal and
esophageal cancer [7-9,19,20]. It was also suggested that
up-regulation of VEGF189 might result in increased angio-
genesis, tumour growth and metastasis in a colon cancer
cell line [21]. Moreover, VEGF189 has been demonstrated
to be a potent permeability factor in vivo [22], supporting
the role of this isoform in the control of angiogenesis.
VEGF165 has also been demonstrated to play an important
role in tumourigenesis. When different isoforms of VEGF
were transfected into the VEGF-null cells in isolation and
the transfected cells were implanted into nude mice, it was
found that VEGF165 was the most prominent isoform that
can fully rescue expansion of the angiogenesis-deficient
tumour, while VEGF121  and VEGF189  only partially or
failed completely to rescue tumour growth, respectively
[23]. However, these authors suggested that VEGF iso-
forms work in a coordinated fashion to recruit and expand
tumour vasculature. In our study we found that although
VEGF165  was predominately expressed in colorectal
tumour tissues, its expression was significantly correlated
with smaller tumour size (maximum diameter less than 5
cm.). Although expression of VEGF121 mRNA has been
previously reported to be correlated with lymph node
metastasis [10] of primary lung cancer and the invasive-
ness of bladder cancer [24], in our study we found that
level of the 18 kDa VEGF protein, which believed to be
VEGF121 [16], was equally expressed in both normal and
tumour tissues of colorectal, and predominately expressed
in normal tissues of the lung.
Detection of VEGF has long been known as a potential
serum diagnostic marker for malignant diseases.
Increased serum VEGF concentrations have been meas-
ured in various types of cancer, including, brain, lung, gas-
trointestinal, hepatobiliary, renal and ovarian cancer [25].
However, the relationship between the pattern of the pro-
duction of VEGF protein isoforms in tumours and its con-
centration in the circulation is still unclear. In this study,
we determined the expression pattern of VEGF isoforms in
tumour tissues in relation to the level of total VEGF in a
patient's serum. The comparison of the VEGF level in
serum of cancer patients with that of normal volunteers
revealed that cancer patients possessed significantly (p <
0.001) higher levels of VEGF in serum. However, some
normal volunteers also possessed quite a high level of
VEGF, which may due to the possibility that normal tis-
sues, like lung tissue (Figure 1) can also produce VEGF121
that is secretable into the circulation. In addition, no sig-
nificant relationship between level of circulating VEGF
and pathologic features was observed.
Conclusion
Our findings indicate that the expression patterns of VEGF
isoforms are altered during tumourigenesis as certain iso-
form overexpression in tumour tissues correlated with
tumour progression indicating their important role in
tumour development. However, measurement of circulat-
ing VEGF in serum may have limited use as a tumour
Table 2: Serum level of VEGF in colorectal and non-small cell lung cancer patients in comparison to healthy volunteers (p < 0.05 was 
considered significant)
Type of sample No. of cases VEGF concentration (pg/ml) p valuea
Colorectal cancer patients 38 1,081 ± 652b <0.001
Lung cancer patients 18 1,251 ± 568 <0.001
Healthy volunteers 47 543 ± 344
aMann-Whitney test, bmean ± SDBMC Cancer 2005, 5:128 http://www.biomedcentral.com/1471-2407/5/128
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marker. This may be due to the following reasons: 1) The
VEGF isoform that appeared to be significantly correlated
with tumour progression is VEGF189, which is the cell-
associated isoform, is not soluble. 2) Some normal tis-
sues, i.e. lung (as shown in Figure 1), expressed high-level
VEGF isoforms (VEGF121) that secreted into the circula-
tion. 3) Expression of some secretable VEGF isoforms
(VEGF165) was negatively correlated with the progression
of tumour size, thus its level may not positively indicate
the stage of the tumour. 4) As has been previously
reported, other physiologic and pathologic condition, i.e.,
pregnancy, RA and cardiovascular diseases can also cause
the induction the circulating level of VEGF [26,27].
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